In patients who have acute myocardial infarction with cardiogenic shock, early revascularization of the culprit artery by means of percutaneous coronary intervention (PCI) improves outcomes. However, the majority of patients with cardiogenic shock have multivessel disease, and whether PCI should be performed immediately for stenoses in nonculprit arteries is controversial.
T h e ne w e ngl a nd jou r na l o f m e dicine T he mortality associated with cardiogenic shock in acute myocardial infarction can be reduced with the use of early revascularization, predominantly percutaneous coronary intervention (PCI), to restore blood flow to the culprit coronary artery. [1] [2] [3] Up to 80% of patients who have cardiogenic shock present with multivessel coronary artery disease, 4 and mortality is higher with multivessel disease than with single-vessel disease. [5] [6] [7] The value of performing immediate PCI for clinically important stenoses of major nonculprit coronary arteries is controversial, and to our knowledge, randomized trials that have addressed this issue have not included patients with cardiogenic shock. [8] [9] [10] [11] Several theoretical arguments support immediate revascularization of all coronary arteries with clinically important stenoses or chronic total occlusions in addition to the culprit lesion, particularly in patients with cardiogenic shock. The most notable argument is the potential to improve overall myocardial perfusion and function. However, immediate multivessel PCI might pose additional risks, such as induction of further is chemia, volume overload, and renal impairment due to the use of an increased dose of contrast material. Current evidence from nonrandomized studies involving patients with cardiogenic shock suggests that mortality at short-term follow-up is higher after immediate multivessel PCI than after PCI of the culprit lesion only. 12 Guideline recommendations differentiate between stable and unstable hemodynamic status. 13, 14 European guidelines recommend the consideration of immediate PCI of nonculprit lesions in patients with cardiogenic shock. U.S. guidelines give no specific recommendation. However, recent U.S. appropriateuse criteria indicate that it is appropriate to perform immediate revascularization of a nonculprit artery if cardiogenic shock persists after revascularization of the culprit artery. [13] [14] [15] The Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock (CULPRIT-SHOCK) trial was designed to test the hypothesis that PCI of the culprit lesion only, with the option of staged revascularization of nonculprit lesions, would result in better clinical outcomes than immediate multivessel PCI among patients who have multivessel coronary artery disease and acute myocardial infarction with cardiogenic shock.
Me thods

Trial Design and Oversight
The trial design has been published previously. 4 This investigator-initiated, randomized, open-label, European multicenter trial involved patients who had acute ST-segment elevation or non-ST-segment elevation myocardial infarction that was complicated by cardiogenic shock, with planned early revascularization by means of PCI and an identifiable culprit lesion. The protocol (available with the full text of this article at NEJM.org) was designed by the principal investigator and was modified and approved by the steering committee 4 ; it was also approved by all relevant ethics committees. The trial was registered at ClinicalTrials.gov 4 months after enrollment of the first patient, as discussed in the Supplementary Appendix (available at NEJM.org).
The institutions that funded the trial had no involvement in the conduct of the trial. A coordinating research organization, Institut für Herzinfarktforschung (Institute for Myocardial Infarction Research), maintained the data and performed independent statistical analysis. The steering committee vouches for the integrity and completeness of the data, and the statistician vouches for the accuracy of the data analysis and the fidelity of the trial to the protocol.
Patients
Patients were eligible for the trial if they had acute myocardial infarction with cardiogenic shock. Additional eligibility criteria were planned early revascularization by means of PCI, multivessel coronary artery disease (defined as at least two major vessels [≥2 mm in diameter] with >70% stenosis of the diameter), and an identifiable culprit lesion. Criteria for cardiogenic shock included a systolic blood pressure of less than 90 mm Hg for longer than 30 minutes or the use of catecholamine therapy to maintain a systolic pressure of at least 90 mm Hg, clinical signs of pulmonary congestion, and signs of impaired organ perfusion with at least one of the following manifestations: altered mental status, cold and clammy skin and limbs, oliguria with a urine output of less than 30 ml per hour, or an arterial lactate level of more than 2.0 mmol per liter.
Exclusion criteria were resuscitation for longer PCI Str ategies in Patients with Cardiogenic Shock than 30 minutes, no intrinsic heart action, an assumed severe deficit in cerebral function with fixed dilated pupils, an indication for primary urgent coronary-artery bypass grafting, single-vessel coronary artery disease, a mechanical cause of cardiogenic shock, the onset of shock more than 12 hours before randomization, an age of more than 90 years, shock with a noncardiogenic cause, massive pulmonary embolism, known severe renal insufficiency (creatinine clearance, <30 ml per minute), and other severe concomitant disease associated with a life expectancy of less than 6 months. For all eligible patients, written informed consent was obtained with the use of a prespecified process that varied slightly according to country (see the Supplementary Appendix). 4 Patients with cardiogenic shock who were not eligible for randomization were entered into the prospective CULPRIT-SHOCK registry.
Randomization and Treatment
Patients underwent randomization immediately after diagnostic angiography. Randomization was performed centrally with the use of an Internetbased program with randomly changing blocks of four or six and stratification according to center.
Patients were randomly assigned, in a 1:1 ratio, to one of two initial revascularization strategies: either PCI of the culprit lesion only, with the option of staged revascularization of nonculprit lesions, or immediate multivessel PCI. In all the patients, PCI of the culprit lesion was performed first, with the use of standard interventional techniques. In patients in the culprit-lesion-only PCI group, all other lesions were to be left untreated at the time of the initial procedure. Staged revascularization procedures were encouraged on the basis of the presence of residual ischemic lesions (evaluated by means of noninvasive testing or with the use of fractional flow reserve [FFR]), symptoms, and clinical and neurologic status. In patients in the multivessel PCI group, PCI of all major coronary arteries with more than 70% stenosis of the diameter was to be performed. This included efforts to recanalize chronic total occlusions during the acute phase; the recommended maximum dose of contrast material was 300 ml.
All other interventional therapeutic measures were allowed, independent of the assigned treatment strategy. In particular, the use of mechanical circulatory support was left to the discretion of the operator. Further therapy was provided in the intensive care unit (ICU) in accordance with generally accepted intensive care guidelines. If renal-replacement therapy was deemed to be necessary, the method, duration, and reason for initiation (in accordance with predefined criteria) were documented.
Primary and Secondary End Points
The primary end point was a composite of death from any cause or severe renal failure leading to renal-replacement therapy within 30 days after randomization. Renal-replacement therapy (dialysis, hemofiltration, or hemodiafiltration) was considered for otherwise untreatable volume overload, hyperkalemia (potassium level, >6.0 mmol per liter), severe uremia (blood urea level, >50 mg per deciliter), or persistent severe metabolic acidosis (pH, <7.2). 4 Clinical secondary end points included the individual components of the primary end point, recurrent myocardial infarction, rehospitalization for congestive heart failure, and repeat revascularization. Other secondary end points included time to hemodynamic stabilization, the use of catecholamine therapy and the duration of such therapy, the duration of the ICU stay, the Simplified Acute Physiology Score II (SAPS-II), and the use of mechanical ventilation and the duration of such therapy. For the assessment of renal and myocardial injury, serial measurements of estimated creatinine clearance and creatine kinase and troponin levels were obtained. Procedural success was included as a secondary end point but was not clearly prespecified, and therefore the results are not reported.
Safety end points included bleeding, which was defined as type 2, 3, or 5 on the Bleeding Academic Research Consortium (BARC) scale (with type 2 indicating any overt, actionable sign of bleeding; type 3 bleeding with a decrease in the hemoglobin level of >3 g per deciliter, any transfusion, cardiac tamponade, or intracranial or ocular involvement; and type 5 fatal bleeding), as well as occurrence of stroke. 4, 16 Detailed definitions of the outcome measures and specific information regarding the reporting of individual prespecified end points are provided in the Supplementary Appendix.
T h e ne w e ngl a nd jou r na l o f m e dicine 
Statistical Analysis
To calculate the sample size, we estimated an event rate of the composite primary end point of death or renal-replacement therapy of 38% in the culprit-lesion-only PCI group and 50% in the multivessel PCI group. 4 A sequential statistical design was chosen; one interim analysis was performed after 50% of all the patients who could be evaluated had completed 30 days of follow-up. The global type I error level was 0.05. We calculated that a sample of 684 patients would give the trial 80% power to rule out the null hypothesis of no difference between the two treatment groups in the event rate for the primary end point (at a twosided alpha level of 0.048 for the final analysis). To allow for a withdrawal rate of 3%, 706 patients were recruited. The software used for samplesize calculation was nQuery Advisor, version 7.0 (Statistical Solutions).
All data were analyzed according to the intention-to-treat principle. In addition, sensitivity analyses were performed in the per-protocol and as-treated populations (defined in Fig. S1 Interquartile range 1-6 1-6 * The difference between the two groups in the rate of aspiration thrombectomy would most likely not remain significant after adjustment for multiple testing. † Thrombolysis in Myocardial Infraction (TIMI) grades for blood flow range from 0 to III, with higher grades indicating better flow. TIMI grades were reported by the investigator. T h e ne w e ngl a nd jou r na l o f m e dicine R esult s
Patients
From April 2013 through April 2017, a total of 1075 patients with cardiogenic shock were screened at 83 European centers, and 706 of those patients (65.6%) were randomly assigned to the culpritlesion-only PCI group (351 patients) or the multivessel PCI group (355 patients). Data could be evaluated for 344 patients in the culprit-lesiononly PCI group and for 342 patients in the multivessel PCI group (Fig. S1 in the Supplementary Appendix). Baseline characteristics were well balanced between the two treatment groups (Table 1 ).
Treatment
Procedural characteristics are shown in Table 2 .
Crossover from the culprit-lesion-only PCI group to the multivessel PCI group was reported in 43 patients (12.5%); reasons for crossover are shown in Table S1 in the Supplementary Appendix. Staged revascularization was performed in 61 of the 344 patients (17.7%) in the culprit-lesion-only PCI group. Crossover from the multivessel PCI group to the culprit-lesion-only PCI group was reported in 32 patients (9.4%); reasons for crossover are shown in Table S2 in the Supplementary Appendix. The Thrombolysis in Myocardial Infarction (TIMI) grades for blood flow obtained before and after PCI of the culprit artery did not differ significantly between the two groups. More patients underwent aspiration thrombectomy in the culprit-lesion-only group than in the multivessel PCI group. The overall dose of contrast material was significantly higher and the duration of fluoroscopy was significantly longer in the multivessel PCI group than in the culprit-lesiononly group. There was no significant difference between the two groups with respect to the use of adjunctive medications or devices for mechanical circulatory support. Most patients were treated with multiple antiplatelet and anticoagulant drugs, including aspirin, P2Y 12 inhibitors, glycoprotein IIb/IIIa inhibitors, and unfractionated heparin.
Primary and Secondary End Points
One patient in the multivessel PCI group was lost to follow-up before 30 days. Therefore, 344 patients in the culprit-lesion-only PCI group and 341 patients in the multivessel PCI group were included in the analysis of the primary and secondary end points (Fig. S1 in the Supplementary Appendix).
At 30 days, the rate of the composite primary end point of death or renal-replacement therapy was significantly lower in the culprit-lesion-only PCI group than in the multivessel PCI group (45.9% vs. 55.4%; relative risk, 0.83; 95% confidence interval [CI], 0.71 to 0.96; P = 0.01) (Table 3 and Fig. 1A) . Only minor variation in the relative risk was observed when the analysis was performed in the per-protocol population (44.8% in the culprit-lesion-only PCI group vs. 55.1% in the multivessel PCI group; relative risk, 0.81; 95% CI, 0.69 to 0.96; P = 0.01) or the as-treated population (46.0% in the culprit-lesion-only PCI group vs. 55.1% in the multivessel PCI group; relative risk, 0.83; 95% CI, 0.72 to 0.97; P = 0.02). Prespecified subgroup analyses revealed consistent results across all the subgroups (Fig. 2) .
The rate of death from any cause was significantly lower in the culprit-lesion-only PCI group than in the multivessel PCI group (43.3% vs. 51.6%; relative risk, 0.84; 95% CI, 0.72 to 0.98; P = 0.03) ( Table 3 and Fig. 1B) . The causes of death are shown in Table S3 in the Supplementary Appendix. The rate of renal-replacement therapy did not differ significantly between the culprit-lesiononly PCI group and the multivessel PCI group (11.6% and 16.4%, respectively; relative risk, 0.71; 95% CI, 0.49 to 1.03; P = 0.07) ( Table 3 and Fig. 1C) . The rates of recurrent myocardial infarction, rehospitalization for congestive heart failure, bleeding, and stroke did not differ significantly between the two groups (Table 3) . Event rates for the primary end point and its components among patients in the CULPRIT-SHOCK registry are shown in Table S4 in the Supplementary Appendix.
The time to hemodynamic stabilization, the use of catecholamine therapy and the duration of such therapy, the duration of the ICU stay, and the use of mechanical ventilation and the duration of such therapy did not differ significantly between the two groups ( Table 2 ). There was also no significant difference between the two groups in the SAPS-II score. The creatinine clearance and levels of arterial lactate, troponin, and creatine kinase were similar in the two treatment groups. 
Discussion
In this randomized, multicenter trial involving patients with multivessel coronary artery disease and acute myocardial infarction with cardiogenic shock, PCI of the culprit lesion only (with the option of staged revascularization of nonculprit lesions) was superior to immediate multivessel PCI with respect to a composite end point of death or renal-replacement therapy at 30 days. The difference was driven mainly by significantly lower mortality in the culprit-lesion-only PCI group.
Multivessel coronary artery disease is present in the vast majority of patients who have acute myocardial infarction with cardiogenic shock and is associated with higher mortality than singlevessel disease. 5 Thus, mortality at 30 days was higher in this trial than in other randomized trials involving patients with cardiogenic shock, despite similar inclusion criteria regarding cardiogenic shock. 2, [17] [18] [19] Although PCI of the culprit lesion is the established standard of care, the management of nonculprit lesions is the subject of intense debate. Complete revascularization has been thought Rehospitalization for congestive heart failure 1/344 (0. Table S3 in the Supplementary Appendix. † On the Bleeding Academic Research Consortium (BARC) scale, type 2 indicates any overt, actionable sign of bleeding; type 3a, overt bleeding with a decrease in the hemoglobin level of 3 to less than 5 g per deciliter or any transfusion; type 3b, overt bleeding with a decrease in the hemoglobin level of 5 g or more per deciliter, cardiac tamponade, or surgical intervention; type 3c, intracranial hemorrhage or intraocular bleeding; type 5a, probable fatal bleeding; and type 5b, definite fatal bleeding. to be beneficial in improving ventricular function and hemodynamic status. 13 However, the results of this trial and of nonrandomized studies have shown lower mortality with PCI of the culprit lesion only than with multivessel PCI. 12 The lack of benefit of immediate multivessel PCI in this trial might be related to the significantly higher dose of contrast material that was used in the multivessel PCI group than in the culprit-lesion-only PCI group and a consequent decline in renal function. However, the incidence of severe renal failure leading to renal-replacement therapy did not differ significantly between the two groups. The higher dose of contrast material that was used in the multivessel PCI group than in the culprit-lesion-only PCI group may have also led to acute left ventricular volume overload and a subsequent negative effect on myocardial function and recovery. In addition, the prolonged duration of the multivessel PCI procedure may be hazardous at a time when the patient is hemodynamically compromised.
The findings of this trial are in contrast with the results of trials involving hemodynamically stable patients with myocardial infarction, which have shown a lower rate of major adverse cardiac events with either angiographically guided or FFRguided early multivessel PCI than with PCI of the culprit lesion only. [8] [9] [10] [11] 20 However, these findings were driven mainly by the difference in the rate of repeat revascularization, which was counted as part of a composite end point, because repeat revascularization was usually performed during follow-up as staged revascularization procedures in patients who initially underwent PCI of the culprit lesion only. In our trial, staged revascularization was encouraged and not counted as a disadvantage of the culprit-lesion-only PCI strategy. In previous trials involving hemodynamically stable patients with myocardial infarction, there were no significant differences between the two treatment strategies in mortality or the rate of recurrent infarction. Among patients with cardiogenic shock, the acute hazards of a prolonged procedure time (including the increased dose of contrast material) seem to outweigh any potential negative aspects of repeat revascularization.
In contrast with previous trials involving highly selected patients with stable infarction, this trial did not specify the presence of a chronic total occlusion as an exclusion criterion. [8] [9] [10] [11] This allowed for inclusion of a real-world cohort of patients with multivessel disease and cardiogenic shock. Chronic total occlusion is frequently present in patients with cardiogenic shock and is associated with adverse clinical outcomes. 21, 22 Exclusion of patients with a chronic total occlusion would have led to a major selection bias and a lower-risk cohort. Therefore, in the multivessel PCI group, immediate recanalization of a chronic total occlusion was recommended. However, it was also advised to pursue recanalization attempts cautiously and to limit the total dose of contrast material to 300 ml. Complete revascularization was achieved in 81% of the patients in the multivessel PCI group. A previous trial involving patients with stable infarction showed no benefit of recanalization for chronic total occlusion of nonculprit lesions. 23 This trial has several limitations. First, blinding was not possible because of the nature of the intervention. Management of cardiogenic shock involves a complex series of clinical decisions, and it is not possible to fully eliminate some bias during the actual course of treatment. Second, some patients could not be evaluated because of difficulties in obtaining final informed consent. The withdrawal rate was at the exact anticipated level of 3%. Third, 75 patients crossed over from their assigned treatment to the other treatment. Of these patients, 14 in the culpritlesion-only PCI group underwent immediate multivessel PCI for multiple reasons, including lack of hemodynamic improvement, plaque shifts, and the presence of newly detected lesions after treatment of the culprit lesion; these reasons suggest that the treatment strategy may require adaptation to the specific clinical circumstances.
In conclusion, this randomized, multicenter trial showed that, among patients who had multi- Shown are Kaplan-Meier time-to-event curves for the primary end point of a composite of death from any cause or severe renal failure leading to renal-replacement therapy (Panel A), as well as the individual components of death from any cause (Panel B) and renalreplacement therapy (Panel C), within 30 days after randomization. PCI denotes percutaneous coronary intervention.
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